Epigenetic biomarkers in prostate cancer: Current and future uses.

Karen Chiam, Carmella Ricciardelli, Tina Bianco-Miotto

    Research output: Contribution to journalReview articlepeer-review

    68 Citations (Scopus)


    Epigenome alterations are characteristic of nearly all human malignancies and include changes in DNA methylation, histone modifications and microRNAs (miRNAs). However, what induces these epigenetic alterations in cancer is largely unknown and their mechanistic role in prostate tumorigenesis is just beginning to be evaluated. Identification of the epigenetic modifications involved in the development and progression of prostate cancer will not only identify novel therapeutic targets but also prognostic and diagnostic markers. This review will focus on the use of epigenetic modifications as biomarkers for prostate cancer.

    Original languageEnglish
    Pages (from-to)248-256
    Number of pages9
    JournalCancer Letters
    Issue number2
    Publication statusPublished - 28 Jan 2014


    • Biomarkers
    • DNA methylation
    • Epigenetics
    • Histone modifications
    • MicroRNAs
    • Prostate cancer


    Dive into the research topics of 'Epigenetic biomarkers in prostate cancer: Current and future uses.'. Together they form a unique fingerprint.

    Cite this